StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the stock.

Separately, Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Down 1.0 %

VNRX stock opened at $0.69 on Thursday. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The firm has a 50-day moving average of $0.69 and a two-hundred day moving average of $0.68. The firm has a market capitalization of $63.94 million, a PE ratio of -1.92 and a beta of 1.10.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its position in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is currently owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.